Stopping Disease in its Tracks with Precision Monocyte Targeting
New Biology. Broad potential. Patients First.
Clinical-Stage company developing therapies for I&I
New Adhesion Checkpoint Discovered
We are focused on development of novel therapies for patients with immune inflammatory indications. Our main program is based on the discovery of a novel adhesion checkpoint, that controls the ability of certain immune cells to reach inflamed tissues.
Our Monocyte Targeting Technology
Our lead clinical-stage candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from traveling to inflammatory tissues. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
Potential for Highly Prevalent and Rare Inflammatory Indications
Following demonstration of disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non-Alcoholic Steatohepatitis, IW-601 is currently being studied in the POINTGUARD Phase 1 clinical trial. The Single Ascending Dose stage of the trial was completed successfully. Multiple catalysts are expected in 2025-2026.
